EXPLORE CALENDAR
Calendar of Events
S Sun
M Mon
T Tue
W Wed
T Thu
F Fri
S Sat
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
1 event,
Non-Dilutive Funding for Life Sciences: G2G’s Monthly GBG Reporting Service Webinar
Non-Dilutive Funding for Life Sciences: G2G’s Monthly GBG Reporting Service Webinar
Every third Thursday of the month, G2G hosts this online event to give bioscience companies (e.g. therapeutics, diagnostics, medical device, digital health, etc.) the chance to learn about non-dilutive funding opportunities
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
0 events,
EVENTS ARCHIVE
From Pandemic to Endemic: How Vaccines are the Nexus for Science, Policy & Public Health in Stopping Pandemics
As we near the two-year mark of the COVID-19 pandemic, many are asking “what’s next.” While more than half of Americans are fully vaccinated, we are still seeing COVID cases rise. Vaccine hesitancy persists and deaths among the unvaccinated are prevalent and critical. We are continuing to learn best practices to navigate this pandemic, but what steps can we really take to turn this into an endemic? Please join our panel of experts to learn how science, policy, and public health working together is key and how we can use these lessons to prepare for future pandemics.
Non-Dilutive Funding: G2G’s Monthly GBG Report Highlights Call & Screen Share 2021
Every third Friday of the month, G2G hosts this online event to give bioscience companies intel on the latest grants and how to access government funding. Join us!
Effective Drug Treatment Requires Engagement: Addressing the Opioid Crisis
During the COVID pandemic, drug overdose deaths rose by almost 30% in the U.S. — the highest number ever recorded, according to the US Centers for Disease Control and Prevention (CDC). We are in the midst of a “fourth wave” of high mortality involving methamphetamine and cocaine use in the United States. This stimulant-related escalation in overdose deaths demands an effective long-term approach. With no FDA-approved medication for Stimulant Use Disorder, the best solution is Contingency Management.